Current Edition


In major shake-up, Novartis combines pharma, oncology units, leaving cancer commercial head, CMO out of job

Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover even ahead of a possible spinoff of generics unit Sandoz, pushing out three …

Continue Reading →

JPM 2022: Vertex’s Trikafta holds the line as company lays groundwork for gene editing launch

Vertex Pharmaceuticals is well known for its slew of cystic fibrosis medications, and newcomer Trikafta is pulling its weight. Over the course of 2021, the …

Continue Reading →

A Guide for Establishing and Governing Data Collection Standards

Many data management teams report that their standards initiatives have stalled or failed because executives aren’t bought-in, standards are over-proliferated, or they are stuffed with …

Continue Reading →
Acceleron Pharma

Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators’ review time only one benefit

Merck & Co.’s $11.5 billion bid for Acceleron Pharma is hitting a delay just as activist investors threaten to derail the deal altogether. Merck has …

Continue Reading →

Roche’s Polivy to hit $2.4B as doctors expect ‘significant switching’ in newly diagnosed lymphoma: analyst

Roche Pharmaceuticals CEO Bill Anderson recently pegged lymphoma drug Polivy’s potential expansion into newly diagnosed patients as a multibillion-dollar opportunity. Now, at least one analyst …

Continue Reading →

DelMar Pharmaceuticals boosted on positive clinical trials update for VAL-083

Shares in DelMar Pharmaceuticals Inc surged over 10% Tuesday on Nasdaq Shares in DelMar Pharmaceuticals Inc (NASDAQ:DMPI) surged over 10% Tuesday as it gave positive …

Continue Reading →

Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of chronic …

Continue Reading →